{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:41:53Z","timestamp":1759380113560,"version":"build-2065373602"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emerging new variants of severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) needs booster vaccination. We evaluated the long\u2010term safety and immunogenicity of heterologous boosting with a SARS\u2010CoV\u20102 messenger RNA vaccine SYS6006. A total of 1000 participants aged 18 years or more who had received two (Group A) or three (Group B) doses of SARS\u2010CoV\u20102 inactivated vaccine were enrolled and vaccinated with one dose of SYS6006 which was designed based on the prototype spike protein and introduced mutation sites. Adverse events (AEs) through 30 days and serious AEs during the study were collected. Live\u2010virus and pseudovirus neutralizing antibody (Nab), binding antibody (immunoglobulin G [IgG]) and cellular immunity were tested through 180 days. Solicited all, injection\u2010site and systemic AEs were reported by 618 (61.8%), 498 (49.8%), and 386 (38.6%) participants, respectively. Most AEs were grade 1. The two groups had similar safety profile. No vaccination\u2010related SAEs were reported. Robust wild\u2010type (WT) live\u2010virus Nab response was elicited with peak geometric mean titers (GMTs) of 3769.5 (Group A) and 5994.7 (Group B) on day 14, corresponding to 1602.5\u2010 and 290.8\u2010fold increase versus baseline, respectively. The BA.5 live\u2010virus Nab GMTs were 87.7 (Group A) and 93.2 (Group B) on day 14. All participants seroconverted for WT live\u2010virus Nab. Robust pseudovirus Nab and IgG responses to wild type and BA.5 were also elicited. ELISpot assay showed robust cellular immune response, which was not obviously affected by virus variation. In conclusion, SYS6006 heterologous boosting demonstrated long\u2010term good safety and immunogenicity in participants who had received two or three doses of SARS\u2010CoV\u20102 inactivated vaccine.<\/jats:p>","DOI":"10.1002\/jmv.29542","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T06:06:39Z","timestamp":1710914799000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010term immunogenicity and safety of heterologous boosting with a SARS\u2010CoV\u20102 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine"],"prefix":"10.1002","volume":"96","author":[{"given":"Jianying","family":"Huang","sequence":"first","affiliation":[{"name":"Clinical Trial Center Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzheng","family":"Qiu","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[{"name":"Clinical Trial Center Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Trial Center Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Hu","sequence":"additional","affiliation":[{"name":"Clinical Trial Center Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhong","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Lin","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixian","family":"Guo","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyu","family":"Yang","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd. Shijiazhuang Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center Zhongnan Hospital of Wuhan University Wuhan Hubei China"},{"name":"Department of Urology Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organization. Coronavirus Disease (COVID\u201019) Dashboard. Accessed August 27 2023.https:\/\/covid19.who.int\/"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization. COVID\u201019 Vaccine Tracker\u2010approved vaccines. Updated 2 Dec 2022. Accessed August 27 2023.https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/#vaccine-list"},{"key":"e_1_2_9_4_1","first-page":"162","article-title":"SARS\u2010CoV\u20102 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli AM","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27688"},{"key":"e_1_2_9_6_1","unstructured":"WHO SAGE roadmap on uses of COVID\u201019 vaccines in the context of OMICRON and substantial population immunity. Accessed August 27 2023.https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Vaccines-SAGE-Roadmap"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119358"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02249-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00681-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01677-z"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00087-X"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2174779"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-069989","article-title":"Effectiveness of heterologous and homologous covid\u201019 vaccine regimens: living systematic review with network meta\u2010analysis","volume":"377","author":"Au WY","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac430"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051576"},{"key":"e_1_2_9_18_1","unstructured":"China National Medical Products Administration.Guidelines for Grading Adverse Events in Clinical Trials of Prophylactic Vaccines (2019 edition). Accessed August 27 2023. Available from:https:\/\/www.nmpa.gov.cn\/yaopin\/ypggtg\/ypqtgg\/20191231111901460.html"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn2688"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01704-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00681-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.01.032"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101680"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn7591"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.29542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:26:25Z","timestamp":1759379185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.29542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/jmv.29542"],"URL":"https:\/\/doi.org\/10.1002\/jmv.29542","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29542"}}